



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
17.12.2003 Bulletin 2003/51

(51) Int Cl.7: **G01N 33/68, C07K 16/18**

(21) Application number: **02012583.7**

(22) Date of filing: **06.06.2002**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **ABETA GmbH**  
**69120 Heidelberg (DE)**

(72) Inventors:  
• **Hartmann, Tobias, Dr.**  
**D-69120 Heidelberg (DE)**  
• **Eikenberg, Oliver, Dr.**  
**D-69221 Dossenheim (DE)**

• **Antz, Christof, Dr.**  
**D-72070 Tübingen (DE)**

(74) Representative: **Schüssler, Andrea, Dr.**  
**Kanzlei Huber & Schüssler**  
**Truderinger Strasse 246**  
**81825 München (DE)**

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio**

(57) Described is a method for the diagnosis of Alzheimer's Disease (AD) or of a risk for developing said disease which is based on the determination of the ratio of hA $\beta$ 42:hA $\beta$ 40 (A $\beta$ 42/40-ratio). A lower A $\beta$ 42/40-ratio

as compared to the normal ratio is indicative for AD or for a risk for developing AD. Moreover, kits are described suitable for carrying out said diagnostic method.

## Description

[0001] The present invention relates to a method for the diagnosis of Alzheimer's Disease (AD) or of a risk for developing said disease which is based on the determination of the ratio of  $\text{hA}\beta 42:\text{hA}\beta 40$  ( $\text{A}\beta 2/40$ -ratio). A lower  $\text{A}\beta 42/40$ -ratio as compared to the normal ratio is indicative for AD or for a risk for developing AD. The present invention also provides kits suitable for carrying out said diagnostic method.

[0002] For the diagnosis of Alzheimer's Disease (AD) and for distinguishing AD from other dementia various methods or combinations thereof are used. These diagnostic methods comprise the "scanning" of the brain using computer tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET) in order to visualize abnormalities in the brain. Another diagnostic approach is the mini-mental state examination (MMSE) which is based on the testing of particular cognitive problems (short-term memory, long-term memory, repetition tests), thus, allowing a distinct evaluation of the patient's capability as regards resolving of problems, linguistic competence etc. According to neurologists, geriatricians and psychiatrists who are familiar with a variety of dementia this test allows a precise diagnosis. Thus, MMSE forms the basis of current diagnosis.

[0003] An additional diagnostic method is based on the determination of compounds which are characteristic of the disease (biochemical markers, biomarkers) in body fluids like blood, liquor, urine etc. using selective laboratory tests. This approach allows the determination of changes of the concentrations due to the disease - even early in the course of the disease, when clinical symptoms might be mild and vague. However, this assay is problematic, since low concentrations of biochemical markers have to be determined selectively for early diagnosis and for exactly distinguishing between AD and other dementia. In order to enhance diagnostic accuracy, particular biochemical markers like the  $\beta$ -amyloid protein and the tau protein are used. The cerebrospinal fluid (CSF) level of tau has been suggested to reflect neuronal and axonal degeneration or possibly formation of neurofibrillary tangles. Accordingly, tau is regarded as a general biomarker for a neuronal dysfunction (Creutzfeldt-Jacob, AD etc.).

[0004] Currently, amyloid  $\beta$  ( $\text{A}\beta$ ) is regarded as the most important diagnostic parameter, since this peptide is responsible for the plaque like extracellular depositions (amyloidosis) in the brain which is a characteristic feature early in the course of AD.  $\beta$ -amyloid is generated by the degradation of the cell membrane protein APP (amyloid precursor protein) by particular enzymes, i.e.  $\alpha$ -,  $\beta$ - and  $\gamma$ -secretases. The biological function of cellular APP still remains enigmatic. APP is part of a superfamily from which sixteen homologous amyloid precursorlike proteins (APLP) and APP species homologues are derived. APP is an ubiquitous glycoprotein expressed highly in neurons. APP deficient mice are viable and develop normally, but they display minor defects that differ according to the null strain, e.g., copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Thus, APP is not required for the expression of a critical cell function, but may be involved in the modulation of neuronal functions at the cellular level. Cleavage of APP by  $\beta$ -secretases results in the formation of soluble fragments of APP, which are further degraded to various amyloid species by  $\gamma$ -secretases. So far, various amyloid species could be identified according to their amino acid sequences and classified according to different lengths (39 to 42 amino acids) and N-termini (e.g., Val 40 =  $\text{A}\beta$  x-40; Ala 42 =  $\text{A}\beta$  x-42, Val 43 =  $\text{A}\beta$  x-43). These peptides are also present in healthy individuals, however, in case of AD etc. their concentrations are different which might be diagnostically relevant. Unfortunately, even in healthy individuals, the concentrations of these biomarkers vary due to age, sex, nutrition, diabetes mellitus, function of the liver or kidneys, oxidative stress as well as genetic factors (e.g. ApoE-gene mutations), thus, impeding exact diagnosis. So far, none of these biomarkers has been accepted for clinical routine diagnostic.

[0005] Since some years the parameter amyloid beta ( $\text{A}\beta$ ), in particular  $\text{A}\beta 40$ , is used as a specific biomarker for the diagnosis of AD. The determination of the presence or concentration of biomarkers like  $\text{A}\beta$  is mainly based on biochemical assays, e.g. immunochemical assays. In liquor,  $\text{A}\beta 40$  (which is involved in regulation) is the predominant species (about 90%) compared to  $\text{A}\beta 42$  (about 5-10%). In contrast to other  $\text{A}\beta$  species,  $\text{A}\beta 42$  is capable of forming aggregates.

[0006] In a recent study, the levels of  $\text{A}\beta 40$  and  $\text{A}\beta 42$  of AD patients and of healthy individuals were compared. It could be shown that there were no differences in both groups as regards the levels of  $\text{A}\beta 40$ , however, AD patients showed decreased levels of  $\text{A}\beta 42$ . Unfortunately, the absolute concentrations of  $\text{A}\beta 42$  observed in various AD patients differ dramatically, i.e. in different studies the following mean values were found: 280 pg/ml, 384 pg/ml, 497 pg/ml, 537 pg/ml, 740 pg/ml and 835 pg/ml. These variations of values of absolute concentrations show that the data obtained have been affected by various factors (state of the sample, assay system used, etc.). Accordingly, the establishing of limit values which is required for the development of a reliable diagnostic assay is almost impossible. Moreover, in the course of sporadic AD disease various levels of amyloid could be observed. In a recent study, it was found that during an early stage of the disease the concentration of  $\text{A}\beta 40$  decreased. By contrast, the concentration of  $\text{A}\beta 42$  increased, however, with progression of the disease the  $\text{A}\beta 42$  levels decreased resembling normal values. Moreover, it was found for a healthy control group that the levels of  $\text{A}\beta 42$  decreased depending on age, however, no significant difference could be observed between AD patients and patients having other dementia. Accordingly, the determination of the concentration of  $\text{A}\beta 42$  only is not sufficient for precise diagnosis of AD. In other words, at present, there is no reliable

marker available for diagnosing AD or for diagnosing a elevated risk for developing AD.

[0007] Thus, the technical problem underlying the present invention is to provide a marker for the reliable (early) diagnosis of Alzheimer's disease (AD) or of a predisposition for said disease.

[0008] The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

[0009] It has been, surprisingly, found that a reliable diagnosis of AD (or the progression of the disease or the monitoring of the effect of therapeutic drugs) which is independent from the state of the sample, age of the patient, sex etc. can be achieved by determining the ratio of amyloid A $\beta$ 42 concentration to amyloid A $\beta$ 40 concentration (A $\beta$ 42/40-ratio).

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Diagram showing the results of an ELISA using the anti-A $\beta$ 42-antibody G2-11 versus the anti-A $\beta$ 42-antibody G2-13

Figure 2: Comparison of the diagnostic parameters MMSE, A $\beta$ 42, A $\beta$ 40 and A $\beta$ 42/40-ratio

[0010] In the table, the values for MMSE, A $\beta$ 42, A $\beta$ 40 and A $\beta$ 42/40-ratio are given in correlation to medical diagnosis (listed according to declining values).

Figure 3: Diagram representing the results shown in Figure 2

[0011] The present invention, thus, relates to a method for the diagnosis of Alzheimer's Disease (AD) or of a risk for developing said disease, comprising the following steps:

(a) contacting a sample with probes specifically binding to hA $\beta$ 42 and hA $\beta$ 40, respectively; and

(b) determining the amounts of hA $\beta$ 42 and hA $\beta$ 40 in said sample, wherein a lower ratio of hA $\beta$ 42 : hA $\beta$ 40 (A $\beta$ 42/40-ratio) as compared to the normal ratio is indicative for AD or for a risk for developing AD.

[0012] The term "normal ratio" as used herein corresponds to a A $\beta$ 42/40-ratio which can be found in healthy individuals and which is determined by using the average values obtained from at least 10, preferably from at least 100 individuals.

[0013] The determination of the hA $\beta$ 42/40-ratio is useful for prognosis, early diagnosis, for monitoring the progression of the disease and for the diagnosis of a late state of the disease.

[0014] Suitable samples for carrying out the diagnostic method of the invention are cerebrospinal fluid (CSF), blood, serum, plasma or urine. The sample is taken from the patient using routine methods, e.g. CSF is taken by lumbar puncture. The preferred sample is CSF.

[0015] In a preferred embodiment of the diagnostic method the ratio of hA $\beta$ 42:hA $\beta$ 40 (A $\beta$ 42/40 ratio) is less or equal 0.8 times compared to the mean value of the normal ratios obtained by a population of at least 10 healthy individuals. More preferably, the A $\beta$ 42/40 ratio is less or equal 0.6 times compared to the mean value of the normal ratios obtained by a population of at least 10 healthy individuals.

[0016] Any method allowing the determination of the levels of hA $\beta$ 42 and hA $\beta$ 40, respectively, in a sample can be used in the method of the present invention, e.g. immunological assays, size separation, e.g. by gel filtration, amino acid analyses etc. with immunological assays being preferred.

[0017] In an even more preferred embodiment of the method of the present invention, the determination of the A $\beta$ 42/40-ratio is carried out by an immunological assay using antibodies specific for hA $\beta$ 42 and hA $\beta$ 40, respectively, i.e., the anti-hA $\beta$ 42-antibody does not substantially cross-react with hA $\beta$ 40 and, vice versa, the anti-hA $\beta$ 40-antibody does not substantially cross-react with hA $\beta$ 42. Suitable antibodies are commercially available, e.g. the antibody G2-11 (specific for A $\beta$ 42) and G2-10 (specific for A $\beta$ 40), both described in Ida et al., J. Biol. Chem. 271 (1996), 22908-22914 and commercially available from ABETA GmbH, Heidelberg, Germany. A particular preferred antibody against A $\beta$ 42 is the antibody G2-13 which is described in Example 1 below and commercially available from ABETA GmbH, Heidelberg, Germany.

[0018] The term "antibody" as used herein, preferably, relates to antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations. Monoclonal antibodies are made from an antigen containing fragments of the hA $\beta$ 42 peptide and hA $\beta$ 40, respectively, by methods well known to those skilled in the art (see, e.g., Köhler et al., Nature 256 (1975), 495). As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody. Moreover, these include chimeric, single chain, and humanized antibodies.

[0019] In a particularly preferred embodiment of the method of the present invention the anti-hA $\beta$ 42-antibody is

directed to the epitope of hA $\beta$ 42 at amino acid positions 35-42 (MVGGWIA) and the anti-hA $\beta$ 40-antibody is directed to the epitope of hA $\beta$ 40 at amino acid positions 33-40 (GLMVGGVV). These antibodies can be prepared, e.g., according to the procedure described in Ida et al., 1996.

[0020] The term "epitope" as used herein is meant to include any determinant responsible for specific interaction with an antibody molecule. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three-dimensional characteristics as well as specific charge characteristics.

[0021] The probes, e.g. an antibody, can be detectably labelled, for example, with a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, or an enzyme (e.g. horse-radish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, malate dehydrogenase, glucose oxidase, urease, catalase etc.) which, in turn, when later exposed to a substrate will react to the substrate in such a manner as to produce a chemical moiety which can be detected. The probes can also be immobilized on an insoluble carrier, e.g. glass, polystyrene, polypropylene, polyethylene, dextran, nylon, natural and modified celluloses, polyacrylamides, agarose and magnetic beads.

[0022] Examples of immunoassays suitable for the method of the present invention are competitive or sandwich assays, such as the enzyme linked immunosorbent assay (ELISA), the radioimmunoassay (RIA) or Western Blots. Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine.

[0023] In a further preferred embodiment, the method of the present invention is carried out in an ELISA format with a sandwich-ELISA format being even more preferred.

[0024] Suitable ELISA and sandwich-ELISA formats are well known to the person skilled in the art and, furthermore, described in the examples below.

[0025] The method of the present invention can be modified, e.g., by additionally determining the concentration of further biomarkers (ApoE, htau, A $\beta$ 38) which might, in certain cases, further improve the diagnostic value of the method of the invention.

[0026] For use in the diagnostic research discussed above, kits are also provided by the present invention. Such kits are useful for the determining the amounts of hA $\beta$ 42 and hA $\beta$ 40, respectively, in a sample, and comprise specific probes for detection of hA $\beta$ 42 and hA $\beta$ 40. The probes can be detectably labeled as described above. In a preferred embodiment, said kit contains a first monoclonal anti-hA $\beta$ 42-antibody directed to the epitope of hA $\beta$ 42 at amino acid positions 35-42 (MVGGVVIA), preferably the antibody G2-13, and a second monoclonal anti-hA $\beta$ 40-antibody directed to the epitope of hA $\beta$ 40 at amino acid positions 33-40 (GLMVGGVV) and, preferably allows diagnosis, e.g., by ELISA and contains the antibodies bound to a solid support, for example, a polystyrene microtiter dish or nitrocellulose paper, using techniques known in the art. Alternatively, said kits are based on a RIA and contain said antibodies marked with a radioactive isotope. In a preferred embodiment of the kit of the invention the antibodies are labeled with enzymes, fluorescent compounds, luminescent compounds, ferromagnetic probes or radioactive compounds.

[0027] The following Examples illustrate the invention.

#### Example 1: Generation of the anti-hA $\beta$ 42-antibody G2-13

[0028] The antibody was generated essentially according to the method described in Ida et al., 1996. The peptide used as antigen had the following amino acid sequence: CMVGGVVIA. The isotype of G2-13 is IgG1 and it specifically recognizes  $\beta\text{A}_4$ 1-42, C-terminal  $\beta\text{A}_4$ C42. It does not show cross-reactivity with the peptides A $\beta$ 38, A $\beta$ 39 and A $\beta$ 40. Cross-reactivity with A $\beta$ 43 and A $\beta$ 44 is about 10%.

[0029] The characteristics of the antibody G2-13 as regards sensitivity were compared with G2-11. Figure 1 shows the results of the determination of amyloid  $\beta$ 42 concentrations using G2-13 and G2-11, respectively. The C50-value characterizing sensitivity is given. A shift of the curve to the left indicates an increase of sensitivity. It can be inferred from Figure 1 that the sensitivity of the antibody G2-13 is 2-3 times higher compared with antibody G2-11.

#### Example 2: Development of a hA $\beta$ 42/40-specific sandwich ELISA

[0030] ELISA (enzyme-linked immunosorbent assay) is a well known method for the routine diagnosis of particular molecules which is based on a solid phase immunoassay. The sandwich ELISA described below allows the selective and sensitive detection of hA $\beta$ 42 and hA $\beta$ 40, respectively, and, thus, the determination of the hA $\beta$ 42/40-ratio.

[0031] Briefly, ninety-six-wells plates (Maxisorp<sup>TM</sup>, Nunc, Denmark) were coated with the capture-antibody W0-2 described in Ida et al., (1996) (commercially available from ABETA GmbH, Heidelberg, Germany), 5  $\mu\text{g/ml}$ , in coating buffer (50 mM Carbonate Buffer, pH 9.5 - 9.7) overnight at 4°C. The following day, plates were blocked with ELISA blocking agent (Stabil Coat, Surmodics, Minnesota, USA) for 2 hours at room temperature on a plate shaker. Standard

curves were prepared from a stock solution (1 µg/ml) of synthetic amyloid β1-40 peptide and stored at -70°C. The standard curves were diluted in ELISA buffer (80 mM phosphate-buffered saline with 1% bovine serum albumin, 0.05% Tween 20™) to the concentrations in the test range from 10 to 2000 pg/ml. 50 µl secondary biotinylated (detection) antibody G2-13 and G2-11, for the hAβ42 assay, and G2-10, for the hAβ40 assay, together with 50 µl of CSF samples (and standards) were incubated on the plates overnight at 2-8°C. The day after, the plates were washed for 5 times with phosphate buffer (8 mM PBS, pH 7.4) and then 100 µl of horseradish peroxidase-conjugated streptavidin was allowed to bind for 30 min at room temperature on a plate shaker. Plates were developed by adding 100 µl of substrate solution (3,3',5,5'-tetramethylbenzidine; 1-Step-Ultra-TMB, PIERCE, Bonn, Germany). After 10-30 min, the substrate reaction was stopped by addition of 50 µl of 1 M H<sub>2</sub>SO<sub>4</sub> per well, and the plates were read at 450 nm (reference wave length: 650 nm) on a plate reader (Emax, Molecular devices, Gothenburg, Sweden). The same standard curve batches were used on all plates, thus, allowing a quantitative determination of the levels of hAβ42 and hAβ40, respectively. Using this ELISA, concentrations in the range of 100 to 2000 pg/ml can be quantitatively determined. This range of concentrations comprises the hAβ concentrations in human liquor and, accordingly, the described ELISA is diagnostically highly useful. The detection limits for both assays were estimated to be in the range of about 100 pg/ml.

### Example 3: Comparison of the diagnostic parameters MMSE, Aβ42, Aβ40 and Aβ42/40-ratio

[0032] In a study comprising 52 patients the diagnostic parameter mini-mental state examination (MMSE) was compared with the biomarkers Aβ42, Aβ40 and Aβ42/40-ratio. For the determination of the concentrations of Aβ42 and Aβ40, the ELISA described in Example 2 was used. Figure 2 shows a comparison of the results obtained by the determination of the concentration of Aβ42 and Aβ40 and the calculation of the Aβ42/40-ratio with clinical diagnosis (MMSE). The results represented in Figure 2 are additionally shown in Figure 3 as a diagram (correlation of the data as regards Aβ42, Aβ40 and Aβ42/40-ratio with the MMSE-values after classification in particular groups (AD, other dementia, no dementia, depressive)).

[0033] The data obtained and presented in Figures 2 and 3 clearly show that when correlating the MMSE-values with Aβ40- and Aβ42-concentrations, respectively, a significant discrimination between the particular groups is not possible. However, when correlating the Aβ42/40-ratio with the MMSE-value a limit value (cut-off) of < 1.0 is obtained. A Aβ42/40-ratio of < 1.0 is in perfect agreement (100%) with clinical diagnosis (AD) and never gave a false positive diagnosis. The cut-off of 1.0 used in this study corresponds to a Aβ42/40 ratio, which is less or equal 0.8 times compared to the mean value of the normal ratios obtained by a population of at least 10 healthy individuals.

## SEQUENCE LISTING

5           <110> ABETA GmbH

          <120> Assay for the diagnosis of Alzheimer's disease based on  
                  the determination of the ratio of hA $\beta$ 42:hA $\beta$ 40

10           <130> A3025

          <140> EP 02012583.7

          <141> 2002-06-06

          <160> 3

15           <170> PatentIn Ver. 2.1

          <210> 1

          <211> 8

          <212> PRT

          <213> Artificial Sequence

20           <220>

          <223> Description of Artificial Sequence: Antigenic  
                  peptide

          <400> 1

25           Met Val Gly Gly Val Val Ile Ala  
              1                               5

          <210> 2

          <211> 8

30           <212> PRT

          <213> Artificial Sequence

          <220>

          <223> Description of Artificial Sequence: Antigenic  
                  peptide

35           <400> 2

          Gly Leu Met Val Gly Gly Val Val  
              1                               5

40           <210> 3

          <211> 9

          <212> PRT

          <213> Artificial Sequence

          <220>

45           <223> Description of Artificial Sequence: Antigenic  
                  peptide

          <400> 3

          Cys Met Val Gly Gly Val Val Ile Ala  
              1                               5

50

## Claims

- 55   1. A method for the diagnosis of Alzheimer's Disease (AD) or of a risk for developing said disease, comprising the following steps:

(a)contacting a sample with probes specifically binding to hA $\beta$ 42 and hA $\beta$ 40, respectively; and

(b) determining the amounts of hA $\beta$ 42 and hA $\beta$ 40 in said sample, wherein a lower ratio of hA $\beta$ 42:hA $\beta$ 40 (A $\beta$ 42/40-ratio) as compared to the normal ratio is indicative for AD or for a risk for developing AD

- 5 2. The method of claim 1, wherein the ratio of hA $\beta$ 42:hA $\beta$ 40 (A $\beta$ 42/40-ratio) is less or equal 0.8 times compared to the mean value of the normal ratios obtained by a population of at least 10 healthy individuals.
3. The method of claim 2, wherein the ratio of hA $\beta$ 42:hA $\beta$ 40 (A $\beta$ 42/40-ratio) is less or equal 0.6 times compared to the mean value of the normal ratios obtained by a population of at least 10 healthy individuals.
- 10 4. The method of any one of claims 1 to 3, wherein the sample is CSF.
5. The method of any one of claims 1 to 4, wherein the probes are antibodies specific for hA $\beta$ 42 and hA $\beta$ 40, respectively.
- 15 6. The method of claim 5, wherein the anti-hA $\beta$ 1-42-antibody is directed to the epitope of hA $\beta$ 42 at amino acid positions 35-42 (MVGGVVIA) and the anti-hA $\beta$ 40-antibody is directed to the epitope of hA $\beta$ 40 at amino acid positions 33-40 (GLMVGGVV).
- 20 7. The method of claim 5 or 6, wherein the antibodies are monoclonal antibodies.
8. The method of claim 5, wherein the anti-hA $\beta$ 1-42-antibody is G2-13.
9. The method of any one of claims 5 to 8, wherein the method is carried out as ELISA.
- 25 10. The method of claim 9, wherein the ELISA is a sandwich-ELISA.
11. The method of any one of claims 1 to 10, comprising the determination of the concentration of at least one additional biomarker.
- 30 12. A kit suitable for carrying out the method according to any one of claims 1 to 11 comprising a first monoclonal anti-hA $\beta$ 42-antibody directed to the epitope of hA $\beta$ 42 at amino acid positions 35-42 (MVGGVVIA) and a second monoclonal anti-hA $\beta$ 40-antibody directed to the epitope of hA $\beta$ 40 at amino acid positions 33-40 (GLMVGGVV).

35

40

45

50

55

Fig. 1







Fig. 2

Sample	AB1-40 [pg/ml]	AB1-42 [pg/ml]	A42/A40 *Factor 10 ratio	MMSE	
Code 7	2413	244	1,0	5	AD
Code 12	2580	152	0,6	24	AD
Code 15	2970	323	1,1	21	AD
Code 21	4615	633	1,4	26	AD
Code 28	4361	323	0,7	27	AD
Code 32	4107	517	1,3	30	AD
Code 35	3358	324	1,0	11	AD
Code 38	5492	358	0,7	22	AD
Code 39	4229	374	0,9	26	AD
Code 51	4337	418	1,0	20	AD
Code 54	5861	528	0,9	19	AD
Code 65	5594	479	0,9	7	AD
Code 69	5081	356	0,7	21	AD
Code 77	3893	384	1,0	23	AD
Code 78	3818	455	1,2	22	AD
Code 79	2478	278	1,1	23	AD
Code 86	4710	538	1,1	29	AD
Code 87	2759	247	0,9	27	AD
Code 89	3069	334	1,1		AD
Code 94	2589	284	1,1	24	AD
Code 99	3007	295	1,0	23	AD
Code 100	6919	650	0,9	27	AD
Code 102	4738	346	0,7	15	AD
Code 104	4605	420	0,9	23	AD
Code 49	1964	339	1,7		other dementia
Code 85	2227	326	1,5	19	other dementia
Code 96	1975	398	2,0	12	other dementia
Code 98	5039	793	1,6	22	other dementia
Code 107	1106	175	1,6	22	other dementia
Code 18	2978	536	1,8	28	depressive
Code 34	1454	366	2,5	29	depressive
Code 36	2091	394	1,9	23	depressive
Code 41	3050	519	1,7	28	depressive
Code 50	1265	249	2,0	27	depressive
Code 10	5691	768	1,3	28	non dement
Code 13	2879	319	1,1	26	non dement
Code 17	4415	584	1,3	27	non dement
Code 20	7331	843	1,1	28	non dement
Code 27	3702	743	2,0	29	non dement
Code 43	5713	990	1,7	26	non dement
Code 59	3314	589	1,8	27	non dement
Code 63	6250	1274	2,0	28	non dement
Code 64	4952	780	1,6	27	non dement
Code 66	4983	746	1,5	15	non dement
Code 74	4079	774	1,9	27	non dement
Code 83	3495	911	2,6	30	non dement
Code 84	3717	736	2,0	27	non dement
Code 95	1189	255	2,1	26	non dement
Code J25	4079	631	1,5	29	non dement
Code J28	3285	346	1,1	29	non dement
Code J32	3288	563	1,7	30	non dement
Code J34	2251	425	1,9	29	non dement

Fig. 3





European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 02 01 2583

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 01 49875 A (UNIV WASHINGTON) 12 July 2001 (2001-07-12) * the whole document * * abstract * * claims 1-5 * * page 5, line 4 - line 15 * * page 6, line 21 - line 23 * * page 7, line 4 - line 6 * * figure 2C *	1-5, 7, 9-11	G01N33/68 C07K16/18
Y	---	1-12	
X	JENSEN MALENE ET AL: "Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems." MOLECULAR MEDICINE (NEW YORK), vol. 6, no. 4, April 2000 (2000-04), pages 291-302, XP008011178 ISSN: 1076-1551 * the whole document * * page 294, right-hand column, line 1 - page 297, left-hand column, line 2 * * figures 1-3 *	12	
Y	---	1-12	TECHNICAL FIELDS SEARCHED (Int.Cl.7) G01N C07K
X	WO 02 02769 A (BROECKHOVEN CHRISTINE VAN ; KUMAR SINGH SAMIR (BE); VLAAMS INTERUNI) 10 January 2002 (2002-01-10) * page 21, line 1 - page 22, line 10 *	12	
Y	---	1-12	
X	WO 01 35106 A (GANDY SAM ; FRAIL DONALD E (US); AMERICAN HOME PROD (US); PETANESCA) 17 May 2001 (2001-05-17) * claims 15, 20, 24, 25 * * example 1 *	12	
Y	---	1-12	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 December 2002	Examiner Tuytman, A
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/02 (F04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 02 01 2583

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	ABETA, 'Online! XP002225797 Retrieved from the Internet: <URL:http://www.abeta.de/german/produkte.php?ABETA_SID=bb857b686633e102ac9b1e7fe66ca703> 'retrieved on 2002-12-19! * the whole document * -----	1-12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search: 19 December 2002	Examiner Tuynman, A
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EP0 FORM 1500 03 02 (P040311)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 01 2583

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-12-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0149875	A	12-07-2001	AU	2610901 A	16-07-2001
			WO	0149875 A1	12-07-2001
			US	2001044126 A1	22-11-2001
WO 0202769	A	10-01-2002	AU	6912701 A	14-01-2002
			WO	0202769 A1	10-01-2002
WO 0135106	A	17-05-2001	AU	1459201 A	06-06-2001
			WO	0135106 A2	17-05-2001

EPO FORM P0559

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82